Baird Lifts PT on Astrana Health (ASTH) Following Q1 Results

Astrana Health, Inc. (NASDAQ:ASTH) is one of the best small cap stocks to buy for 10x potential. On May 8, Baird lifted the price target on Astrana Health, Inc. (NASDAQ:ASTH) to $45 from $40, maintaining an Outperform rating on the shares. The firm updated its model on the stock after it released its fiscal Q1 2026 financial results, stating that the story is strengthening and the MA margin upside is taking shape. The company also received a rating update from Needham the same day, with the firm lifting the price target on Astrana Health, Inc. (NASDAQ:ASTH) to $41 from $30 and reaffirming a Buy rating on the shares.

Spectral AI (MDAI) Secures $17.7 Million to Launch Burn Wound AI System

In its financial results for fiscal Q1 2026 released on May 7, Astrana Health, Inc. (NASDAQ:ASTH) reported total revenue of $965.1 million, reflecting a 56% year over year growth. It also reported adjusted EBITDA of $66.3 million, up 82% year over year, and free cash flow of $64.1 million, up 372% year over year.

Astrana Health, Inc. (NASDAQ:ASTH) is a physician-centric, technology-powered, risk-bearing healthcare management company that operates as an integrated healthcare delivery platform. It provides services including Multi-Specialty Care, Primary Care, Radiology, Immediate Care, and Laboratory.

While we acknowledge the risk and potential of ASTH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ASTH and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.